Probable drug-induced liver injury associated with aliskiren: Case report and review of adverse event reports from pharmacovigilance databases. - Université de Limoges Accéder directement au contenu
Article Dans Une Revue American Journal of Health-System Pharmacy Année : 2014

Probable drug-induced liver injury associated with aliskiren: Case report and review of adverse event reports from pharmacovigilance databases.

Résumé

PURPOSE: A case of probable drug-induced liver injury (DILI) attributed to use of the antihypertensive agent aliskiren is reported. SUMMARY: A 61-year-old woman undergoing routine liver function monitoring in conjunction with long-term antiepileptic therapy was noted to have an asymptomatic acute hepatic cytolysis 1 month after the initiation of concomitant aliskiren therapy (150 mg/day). Liver enzyme testing showed dramatically elevated aspartate transaminase (AST) and alanine transaminase (ALT) concentrations, with substantial rises also noted in γ-glutamyltransferase (GGT) and alkaline phosphatase (ALP) levels. The calculated ALT:ALP value indicated hepatocellular injury. On discontinuation of aliskiren use, rapid biological improvement occurred, including normalization of serum AST and a sharp decline in serum ALT within one week and the return of GGT and ALP levels to baseline a few weeks later; the patient's AST and ALT concentrations remained normal during 18 months of subsequent monitoring. Using the algorithm of Naranjo et al. and a DILI-specific causality assessment instrument, it was determined that aliskiren use was the probable cause of the patient's liver injury. While this is believed to be the first report of aliskiren-associated DILI in the professional literature, a review of information from several European and North American pharmacovigilance databases (through October 2012) identified 117 reports of suspected aliskiren hepatotoxicity, including 6 reports of liver failure and 12 reports of deaths. CONCLUSION: Asymptomatic acute hepatic cytolysis was observed in a 61-year-old woman approximately one month after initiation of aliskerin for treatment of hypertension. Improvement in AST and ALT concentrations was observed shortly after the drug was discontinued.
Fichier non déposé

Dates et versions

hal-00978390 , version 1 (14-04-2014)

Identifiants

Citer

Sabrina Crepin, Bertrand Godet, Paul Carrier, Claire Villeneuve, Louis Merle, et al.. Probable drug-induced liver injury associated with aliskiren: Case report and review of adverse event reports from pharmacovigilance databases.. American Journal of Health-System Pharmacy, 2014, 71 (8), pp.643-7. ⟨10.2146/ajhp130149⟩. ⟨hal-00978390⟩
32 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More